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Learning Objectives Explain the association between clinical factors and postchemotherapy ovarian function.
Explain the association between biochemical markers and postchemotherapy ovarian function.
Discuss the role that age and anti-Mu¨llerian hormone may play in prediction of postchemotherapy
ovarian function status.
ABSTRACT
Background. Reproductive-aged women frequently receive
both chemotherapy and endocrine therapy as part of their
treatment regimen for early stage hormone receptor-positive
breastcancer.Chemotherapyresults in transientorpermanent
ovarian failure in the majority of women. The difficulty in
determining which patients will recover ovarian function has
implications for adjuvant endocrine therapy decision making.
We hypothesized that pretreatment serum anti-Mu¨llerian
hormone (AMH) and inhibin B concentrations would predict
for ovarian function following chemotherapy.
Methods. Pre- and perimenopausal women aged 25–50 years
with newly diagnosed breast cancer were enrolled. Subjects
underwentphlebotomyforassessmentofserumAMH, inhibinB,
follicle-stimulating hormone, and estradiol prior to chemother-
apy and 1month and 1 year following completion of treatment.
Associations among hormone concentrations, clinical factors,
and biochemically assessed ovarian function were assessed.
Results. Twenty-seven subjects were evaluable for the pri-
mary endpoint.Median agewas 41.Twenty subjects (74.1%)
experienced recovery of ovarian function within 18 months.
Of the 26 evaluable subjects assessed prior to chemother-
apy, 19 (73.1%) had detectable serum concentrations of
AMH. The positive predictive value of a detectable baseline
serum AMH concentration for recovery of ovarian function
was 94.7%, and the negative predictive value was 85.7%. On
univariate analysis, younger age and detectable serum AMH
concentration at chemotherapy initiationwere predictive of
increased likelihood of recovery of ovarian function.
Conclusion. Prechemotherapy assessment of serum AMH
may be useful for predicting postchemotherapy ovarian
function. This finding has implications for decision mak-
ing about adjuvant endocrine therapy in premenopausal
women treated with chemotherapy. The Oncologist 2014;
19:68–74
Implications for Practice: Premenopausal women with breast cancer can develop ovarian failure when treated with
chemotherapy. The ability to accurately predict ovarian function after chemotherapy has implications for both adjuvant
endocrine therapydecisionmakingand future fertilityplanning.Weevaluatedpotential clinical predictorsaswell asbloodmarkers
of ovarian reserve. We identified an association between both younger age and higher serum anti-Mu¨llerian hormone and
increased likelihood of recovery of ovarian function following chemotherapy. This finding could have implications for younger
women who are contemplating future fertility as well as older premenopausal women who aremaking decisions about adjuvant
antihormonal treatment for breast cancer.
INTRODUCTION
Although most breast cancers diagnosed each year in the
United States are in postmenopausal women, a substantial
minority are premenopausal. Menstrual status has both
survivorship and treatment implications. Younger women with
breast cancer are more likely to be treatedwith chemotherapy,
which can lead to cessationofovarian function and consequent
loss of fertility, decreased sexual activity, and higher risk of
long-term adverse medical conditions, such as osteoporosis
and coronary artery disease [1–3]. Chemotherapy causes
temporary amenorrhea in the majority of women, and risk of
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permanent amenorrhea increaseswith age andwith treatment
regimen [4, 5]. Most studies have evaluated presence or ab-
sence of menses, rather than biochemical assessment, as a
measure of ovarian function. Because women can have resid-
ual ovarian function in the absence of menses, and because
factors such as adjuvant endocrine therapy can influence
menses, the impact of chemotherapy on long-term ovarian
function is unclear.
Ovarian function can be challenging to assess, especially in
the postchemotherapy setting. Potential markers of ovarian
reserve includebiochemicalmarkers and imagingassessments
[6,7]. Serumconcentrationsofanti-Mu¨llerianhormone (AMH)
and inhibin B both decrease with declining ovarian function,
whereas follicle-stimulating hormone (FSH) increases [8].
Serum AMH concentration has been shown to be the best
biochemical marker for assessment of decline in reproductive
capacity in healthy women [8]. In addition, imaging with
transvaginal ultrasound can be used to determine antral
follicle count, which may correlate with residual ovarian
function [9]. Limited data in chemotherapy-treated women
with breast cancer have demonstrated that prechemotherapy
serum AMH and inhibin B concentrations predicted for
chemotherapy-related amenorrhea 1 year following chemo-
therapy [10]. Likewise, a second study demonstrated that
serum AMH concentration, but not inhibin levels, was pre-
dictive for continued menses 4–5 years after chemotherapy
administration [11].
Knowledge prior to chemotherapy administration of the
likelihood of ovarian function recovery following chemother-
apy has implications for planning for individual patients; for
example, those who wish to maintain fertility may desire to
undergo embryo or oocyte cryopreservation [12]. For those
whodonotdesire future fertility, knowledgeofpermanent loss
of ovarian function could lead to earlier implementation of
preventivemeasures formenopause-relateddisorders such as
osteoporosis and coronary artery disease. Finally, postchemo-
therapy ovarian function has direct implications for choice of
adjuvant endocrine therapy for hormone receptor-positive
(HR-positive) breast cancer.
Treatment of HR-positive breast cancer with adjuvant
endocrine therapy has been shown to improve disease-free
and overall survival rates. In postmenopausal women,
aromatase inhibitors (AIs) have been shown to be more
effective than tamoxifen [13]; however, in women who are
premenopausal at the time of diagnosis, AIs may cause a
paradoxical rise in estrogen levels resulting from reactivation
of ovarian function. Consequently, even in women who have
developed chemotherapy-induced ovarian failure, tamoxifen
is the standard of care [14, 15].
Taken together, these factors highlight the clinical im-
portance of assessment of ovarian function in pre- or peri-
menopausal women with HR-positive breast cancer who
are treatedwith chemotherapybecause this informationdirectly
affects endocrine therapy decision making. We hypothesized
that low prechemotherapy serum concentrations of AMH and
inhibin Bwould predict for lackof recovery of ovarian function
following chemotherapy. In order to address this hypothesis,
we prospectively evaluated a cohort of premenopausal
women ranging from25 to50yearsof agewhowere initiating
chemotherapy for early stage breast cancer.
MATERIALS AND METHODS
Subjects
This report is derived from a prospective registry study
performed at the University of Michigan Comprehensive
Cancer Center. Women aged 25–50 years who had a
menstrual cycle within 3 months prior to study entry, who
were diagnosed with stage I–III breast cancer, and who
were scheduled to receive neoadjuvant or adjuvant chemo-
therapy were enrolled in the registry between December
2007 and December 2008 (ClinicalTrials.gov identifier
NCT00644683). Prior cytotoxic chemotherapy for any reason,
bilateral oophorectomy, hysterectomy, and pelvic radiation
were prohibited. Subjects who were planning to receive
concomitant gonadotropin-releasing hormone agonist ther-
apy during chemotherapywere ineligible.The clinical protocol
was approved by the University of Michigan institutional
review board, and all subjects provided written informed
consent prior to undergoing any protocol-directed procedures.
Total planned accrual was 28 subjects, with 7 in each age cohort
(25–34 years, 35–39 years, 40–44 years, 45–50 years).
Study Design
After enrollment, each subject underwent phlebotomy, com-
pleted a pastmedical and gynecological history questionnaire,
and initiated treatment with her treating physician’s choice
of adjuvant or neoadjuvant chemotherapy regimen. Phlebot-
omy was repeated 14–42 days and 12–15 months following
completion of chemotherapy. Subjects underwent follow-up 6
months and 12–15 months following completion of chemo-
therapy, by telephone and in person, respectively, to collect
information about recurrence of menses and concomitant
medications. Subjects were instructed to notify the clinic if
they experienced resumption of menses between clinic
visits. Clinical records were reviewed to determine whether
patients experienced resumption of menses following the 12-
to 15-month study visit.
Laboratory Analyses
AMH, inhibin B, and FSH assayswere performed by the Clinical
Ligand Assay Satellite Service laboratory at the University
of Michigan School of Public Health. Serum AMH and in-
hibin B concentrations were measured using the AMH Gen II
ELISA (A73818; Beckman Coulter, Fullerton, CA, http://www.
beckmancoulter.com) and Inhibin B Gen II ELISA (A81301;
Beckman Coulter), respectively, according to the manufac-
turer’s instructions. For AMH, the minimum detectable
concentration was 0.16 ng/mL, the upper level of quantifica-
tion (LOQ) was 22.5 ng/mL, and the inter- and intra-assay
coefficients of variation (CVs) were 7.1% and 2.9%, respec-
tively. For inhibin B, the minimal detectable concentration
was 10 pg/mL, the upper LOQ was 1,000 pg/mL, and the
inter- and intra-assay CVs were 4.3% and 2.8%, respectively.
Serum FSH concentrations were measured using a two-
site chemiluminescence (sandwich) assay [16, 17], which
has a minimum detectable concentration of 0.3 mIU/mL
andan upper LOQof 200mIU/mL. Inter- and intra-assay CVs
were 8.1% and 3.5%, respectively. Serum estradiol concen-
trations were measured using a gas chromatography tandem
www.TheOncologist.com ©AlphaMed Press 2014
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mass spectroscopy assay (InVentiv Health Clinical, Princeton,
NJ, http://www.inventivhealthclinical.com), which has a min-
imal detectable concentration of 0.625 pg/mL [18].
Statistical Analysis
The primary endpoint was recovery of ovarian function
within 18 months of completion of adjuvant or neoadjuvant
chemotherapy. Ovarian function was defined as recurrence
of menses or serum estradiol concentration . 10 pg/mL.
Logistic regression was used to evaluate associations between
clinical and biochemical factors. In univariate analysis, recovery
of ovarian function was the response variable and was tested
against each potential covariate (age at study enrollment; body
mass index; smoking status; use of endocrine therapy; and
serum concentrations of AMH, estradiol, FSH, and inhibin B).
The multivariate analysis included only those factors that were
significant in the univariate analysis. In both the univariate and
multivariate analyses, AMH was evaluated as a dichotomous
variable, divided into detectable levels ($0.16 ng/mL) versus
undetectable levels (,0.16 ng/mL). Values of p , .05 were
considered statistically significant.
RESULTS
Change in Ovarian Function With Chemotherapy
A total of 29 subjects were enrolled into four age cohorts:
25–34 years (n5 6), 35–39 years (n5 8), 40–44 years (n5 7),
and 45–50 years (n5 8) (supplemental online Table 1). After
signing the informed consent document, one subject in the
youngest cohort was determined to be ineligible because
she received gonadotropin-releasing hormone agonist ther-
apy prior to initiation of chemotherapy. Twenty-five of the
27 eligible subjects (92.6%) reported being premenopausal
at the time of enrollment. Two subjects reported being
perimenopausal, defined as having irregular menses in the
setting of previously regular menses. Baseline clinical and
laboratory characteristics of enrolled subjects are listed in
Tables 1 and 2.
At the second study visit, which took place an average of
4.9 weeks (standard deviation [SD]: 2.1 weeks) following
completion of chemotherapy, no subjects were taking ad-
juvant endocrine therapy (tamoxifen, luteinizing hormone-
releasing hormone agonist, and/or AI). Average time since last
menstrual period was 16.3 weeks (95% confidence interval
[CI]: 7.7–24.9). One subject reported continuedmenstruation
during chemotherapy.Two subjects, both of whom had serum
estradiol concentrations.100 pg/mL, reported that menses
had recurred since completing chemotherapy. Of the other 24
subjects with available serum estradiol concentrations, 4 had
levels .10 pg/mL but had not experienced the return of
menses.
At the final assessment an average of 13.6 months (SD:
1.1 months) following chemotherapy, 17 subjects were re-
ceiving treatment with tamoxifen and 6 subjects were not
taking endocrine therapy. Four additional subjects resumed
menstruation following chemotherapy and then started treat-
ment with ovarian suppression or ablation plus AI therapy.
One subject underwent bilateral salpingo-oophorectomy 4
months after completing chemotherapy, prior to resuming
menses, and thus was not evaluable for the primary
endpoint. Twenty of the 27 evaluable subjects (74%) had
experienced recovery of ovarian function since completion
of chemotherapy based on return ofmenses (n5 14) and/or
serum estradiol concentration. 10 pg/mL (n5 10). Seven
of 27 subjects (26%) had not had vaginal bleeding since
completing chemotherapy, and 5 of these subjects were
confirmed to have serum estradiol concentrations in the
postmenopausal range.
Change in Markers of Ovarian Reserve
With Chemotherapy
Prior to chemotherapy, 19 of 26 (73%) and 21 of 25 (84%)
evaluable subjects had serum AMH and inhibin B concen-
trations above the level ofdetection, including3of 7 (43%)and
6 of 7 (86%), respectively, in the oldest age cohort. Two of 26
subjects (8%) had serum FSH concentrations in the post-
menopausal range, defined as .21 mIU/mL; both subjects
were aged.40 years, andone reported irregularmenses prior
to enrollment.
At the assessment 1 month after completion of chemo-
therapy, no subjects with available serum samples had AMH
concentrations above the level of detection (Fig. 1A, Table 2).
Similarly, only 3 of 25 (12%) had inhibin B concentrations
above the level of detection (Fig. 1B, Table 2). Twenty-three
of 25 subjects (92%) had FSH concentrations in the post-
menopausal range (Fig. 1C, Table 2). The subject whose in-
hibin B concentration increased with chemotherapy did not
have a concomitant decrease in FSH concentration.
One year following completion of chemotherapy, 3 of 22
subjects (13%) had serum AMH levels above the level of
detection.These three subjects were all under age 40 and had
recovery of ovarian function (Fig. 1A, Table 2). Among 4 of 22
subjects (18%), one with a detectable AMH level also had
a detectable inhibin B level and three others had detectable
serum inhibin B but not AMH concentrations. Ten of 22 sub-
jects (45%) had FSH concentrations in the postmenopausal
range (Fig. 1C,Table 2). As can be seen in Figure 1C, all but one
of the women aged.40 years had higher FSH concentrations
following chemotherapy, regardless of whether they recov-
ered ovarian function. All subjects with detectable AMH and
half with detectable inhibin B levels had FSH concentrations
below the postmenopausal range.
Markers of Ovarian Reserve and Recovery of
Ovarian Function
Clinical and laboratory factorswereevaluated using univariate
analysis to identify associations with recovery of ovarian
function following chemotherapy. As shown in Table 3, only
younger age at chemotherapy (odds ratio [OR]: 0.72 [95% CI:
0.53–0.97]; p 5 .032) and detectable baseline serum AMH
concentration (OR:108 [95%CI: 5.8 to.2,000];p, .002)were
statistically significantly associated with recovery of ovarian
function. Of the seven subjects without recovery of ovarian
function, six (85.7%) had undetectable serum AMH concen-
trations at baseline. In contrast, of the 19 subjects with serum
samples availablewhohad recoveryofovarian function, only 1
(5%) had an undetectable baseline AMH value. In addition,
there was a trend toward an association between baseline
serum inhibin B concentration and recovery of ovarian
function, with an OR of 1.04 (95% CI: 0.996–1.08; p 5 .075).
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Table 1. Patient characteristics (n5 28)
Characteristic Detail No. of patients (%)
Patient factors
Age, median (range) 41 (25–50)
Race White 23 (82.1)
Black 2 (7.1)
Other 3 (10.7)
Menopausal status Premenopausal 26 (92.9)
Perimenopausal 2 (7.1)
Body mass index ,25 10 (35.7)
25–30 9 (32.1)
.30 9 (32.1)
Smoking status Never 19 (67.9)
Current 3 (10.7)
Former 6 (21.4)
Tumor factors
Histology ER positive 21 (75)
PR positive 18 (64.3)
HER2 positive 12 (42.9)
Treatment regimens
Chemotherapy ddAC 2 (7.1)
ddAC-dd paclitaxel 9 (32.1)
ddAC-weekly paclitaxel 7 (25)
Docetaxel/cyclophosphamide 9 (32.1)
Docetaxel/carboplatin 1 (3.6)
Targeted therapy Trastuzumab 12 (42.9)
Endocrine therapy at 12-mo
postchemotherapy time point
Tamoxifen 14 (50)
AI plus GnRH agonist or BSO 6 (21.4)
None 7 (25)
Unknown 1 (3.6)
Abbreviations: AC, doxorubicin and cyclophosphamide; AI, aromatase inhibitor; BSO, bilateral salpingo-oophorectomy; dd, dose-dense; ER, estrogen
receptor; GnRH, gonadotropin-releasing hormone; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.
Table 2. Markers of ovarian reserve prior to and following chemotherapy in evaluable subjects
Characteristic Baseline 1 mo postchemotherapy 1 yr postchemotherapy
Time since chemotherapy, mean (SD) n.a. 4.9 wk (0–9) 13.4 mo (11–16)
Markers of ovarian reserve
Estradiol, pg/mL, mean (SD) 79.1 (125.2) 18.1 (36.8) 92.5 (145.4)
No. postmenopausal (%) 2/25 (8) 5/24 (20.8) 10/18 (56)
FSH, mIU/mL, mean (SD) 7.6 (8.5) 69.3 (31.5) 32.6 (35.1)
No. postmenopausal (%) 2/26 (8) 23/25 (92) 10/22 (45)
AMH, ng/mL, mean (SD) 1.95 (2.17) ,0.16 0.23 (0.22)
No. above detection (%) 19/26 (73) 0/26 (0) 3/22 (14)
Inhibin B, pg/mL, mean (SD) 50.5 (35.8) 14.9 (19.3) 15.0 (12.2)
No. above detection (%) 21/25 (84) 3/25 (12) 4/22 (18)
Concomitant medications n.a.
Tamoxifen (%) 0 10 (38)
GnRH agonist and/or AI (%) 0 6 (23)
Menses since chemotherapy 3 (11) 15 (58)
Under “Concomitant Medications,” numbers not in parentheses indicate the number of patients.
Abbreviations: AI, aromatase inhibitor; AMH, anti-Mu¨llerian hormone; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; n.a.,
not available; SD, standard deviation.
www.TheOncologist.com ©AlphaMed Press 2014
Henry, Xia, Schott et al. 71
CM
E
None of the factors remained significant in the multivariate
analysis (data not shown).
In an exploratory analysis, conditioned on subjects with
detectable serum AMH concentrations at baseline, the likeli-
hood of ovarian function recovery was 0.998 for subjects aged
,35 years, 0.990 for subjects aged 35–39 years, and 0.95 for
subjects aged 40–44 years.Too few subjects in the cohort aged
45–50 years had detectable baseline AMH concentrations to
perform the analysis.
DISCUSSION
In this study of young women with breast cancer who were
initiating chemotherapy, we observed that older age and pre-
chemotherapy serum AMH concentration below the level of
assay detection were associated with increased likelihood of
biochemically determined ovarian failure at 18 months follow-
ing chemotherapy.The positive predictive value of a detectable
baseline serum AMH concentration for prediction of recovery
of ovarian function after chemotherapy was 94.7%, and the
Figure 1. Change in serum concentrations of ovarian reservemarkers with chemotherapy. Each line signifies an individual subject. Solid
lines: subjects aged.40 years. Dotted lines: subjects aged#40 years. Blue lines: subjects with ovarian failure. Red lines: subjects with
ovarian function recovery. Black bars: mean hormone concentration at each time point. (A): AMH. (B): Inhibin B. (C): FSH. (D): Estradiol.
Abbreviations: AMH, anti-Mu¨llerian hormone; chemo, chemotherapy; FSH, follicle-stimulating hormone.
Table 3. Univariate analysis of the effect of potential covariates on recovery of ovarian function following chemotherapy
Variable Odds ratio (95% confidence interval) p value
Age at enrollment 0.72 (0.53–0.97) .032
Body mass index 0.98 (0.83–1.16) .84
Baseline anti-Mu¨llerian hormone
($0.16 ng/mL vs.,0.16 ng/mL)
108 (5.8 to.2,000) ,.002
Baseline estradiol 1.00 (0.991–1.02) .58
Baseline follicle-stimulating
hormone
0.91 (0.81–1.02) .11
Baseline inhibin B 1.04 (0.996–1.08) .075
Ever smoker (yes vs. no) 1.07 (0.16–7.2) .94
Postchemotherapy endocrine
therapy (yes vs. no)
0.50 (0.05–5.23) .56
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negative predictive value was 85.7%. These findings are con-
sistent with previously published data on prechemotherapy
AMH and biological underpinnings [11].
Our data are also consistent with previous reports that
postchemotherapy AMH and inhibin B serum concentrations
are lower in women treated with chemotherapy compared
withage-matchedhealthycontrols [19–21]. Inacohortofwomen
with a median age of 43 years at the time of chemotherapy,
serum concentrations of both hormones following chemo-
therapy were shown to be associated with chemotherapy-
related amenorrhea [20]. Postchemotherapy serum AMH
concentrations were also lower in a younger cohort of breast
cancer survivors who continued menstruation following
chemotherapy comparedwith healthy controls [19]. Finally,
a recently reported trial of pre- andperimenopausalwomen
who developed chemotherapy-induced ovarian failure and
subsequently started treatment with anastrozole failed to
identify an association between serum AMH concentration
immediately prior to AI initiation and recovery of ovarian
function [22]. Based on these data, postchemotherapy AMH
assessment does not appear to be useful for endocrine
therapy decision making.
Identification of ameasurable factor that could be used to
predict postchemotherapy ovarian reserve would be impor-
tant for management of younger women who are concerned
about ovarian function recovery and future fertility. American
Society of Clinical Oncology guidelines recommend that
oncologists address thepossibilityof infertilitywithall patients
of child-bearing potential who may desire future fertility [12];
however, in practice, fertility-preservation measures are time
consuming and expensive andmay delay initiation of therapy.
If preservation of ovarian function and, more important,
fertility could be better predictedwith a circulating biomarker
such as AMH, then embryo or oocyte preservationmay not be
necessary in a large number of women aged ,40 years who
have a detectable serumAMHconcentration prior to initiation
of standard breast cancer adjuvant chemotherapies.
More applicable to older pre- andperimenopausal women
istheneedtoaccuratelydetermineovarian function inorder to
make treatment decisions about adjuvant endocrine therapy.
It is known that the risk of chemotherapy-induced ovarian
failure increases with increasing age [4, 5]; however, the
absolute age above which oncologists can be certain that
a woman will not have residual ovarian function has not been
established.There is concern that a proportion of womenwho
are believed to have ovarian failure following chemotherapy
may in fact recover ovarian function and thus should not be
treated with AI monotherapy [14, 22]. It has been suggested
that all women who are premenopausal prior to chemother-
apy, even those in their late 40s and early 50s, should be
treatedwith adjuvant tamoxifen therapyor, if they are going to
receive an aromatase inhibitor, should have their ovaries
removed or chemically suppressed [22]. For the latter group,
these strategies are invasive and are associatedwith increased
side effects. Consequently, prediction of permanent ovarian
failure using information other than patient age is of interest.
Although it is known that serum AMH concentration and age
are correlated [8], the data from this study and others [11]
suggest that prechemotherapy assessment of serum AMH
concentrations, or possibly the combination of AMH and
inhibin B, may provide important information about the
likelihood of developing permanent ovarian failure with
chemotherapy and could identify a patient population in
which it is safe to treat with upfront AI monotherapy.
Strengths of our study include prospective, serial assess-
ment of markers of ovarian reserve both before and after
chemotherapy in subjects over a wide age range. In particular,
serial monitoring of subjects permitted assessment of intra-
patient change rather than relying on comparison of pop-
ulation averages. In addition, serum estradiol levels were
assessed using an ultrasensitive assay designed for increased
accuracy at very low estradiol levels, such as those found in
postmenopausal women. This assessment enabled accurate
biochemical assessment of ovarian function, as opposed to
relying on patient self-report of menstrual function.
One limitation is the heterogeneity of administered che-
motherapy regimens; however, the impact of this limitation
is expected to be minimal because all but one subject were
treated with a cyclophosphamide-containing chemotherapy
regimen—the chemotherapy agent that appears to have
the greatest impact on ovarian function—and all regimens
contained similar total doses of the medication. An additional
limitation is the use of adjuvant endocrine therapy by the
majority of subjects at the final assessment. Ovarian function
could still be assessed in those treated with tamoxifen using
theestradiol assay,but thosewhounderwentchemicalovarian
suppression or bilateral oophorectomy were noninformative.
Imaging methodologies such as transvaginal ultrasound
were not performed in this clinical study. Recent research
has suggested that imaging findings such as antral follicle
count may provide additional information regarding ovar-
ian function in chemotherapy-treated women [23]. Most
important, the relatively small sample size limits the
statistical power to detect associations between clinical or
biochemical factors and recovery of ovarian function on
multivariate analysis. Consequently, these data alone do
not provide validated assay cutoffs for either recovery or
permanent loss ofovarian function, andmorework is needed
in order to make measurement of baseline AMH a routine
clinical practice.
CONCLUSION
These results suggest that in women with a serum AMH
concentration of at least 0.16 ng/mL and who are aged ,40
years, ovarian function recovery is likely. In contrast, in older
pre- and perimenopausal women with breast cancer who
undergo treatment with standard adjuvant chemotherapy
regimens, low prechemotherapy serum AMH, and possibly
inhibin B, concentrations may be predictive of permanent
ovarian failure. Currently, data are insufficient to support
routine assessment of these biomarkers prior to chemother-
apy initiation. Prospective validation of this hypothesis is
warranted because these findings could have significant
implications for decision making about adjuvant endocrine
therapy in this cohort of patients.
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FOR FURTHER READING:
Di Paola R, Costantini C, Tecchio C et al. Anti-Mu¨llerian Hormone and Antral Follicle Count Reveal a Late Impairment of
Ovarian Reserve in Patients Undergoing Low-Gonadotoxic Regimens for Hematological Malignancies. The Oncologist
December 2013;18:1307–1314.
Implications for Practice: The need for accurate and personalized counseling of women diagnosed with hematological
malignancies andexposed toanticancer therapy in their reproductiveage is themajor clinical implicationof this study.More
specifically, the study implies that adequate fertility preservation methods should be discussed when therapies with a low
toxicity to the reproductive system are used. Indeed, patients may experience impairment of their reproductive potential,
even several years post-therapy, hampering their fertility wishes. Patients should undergo frequent evaluation of their
fertility potential to detect eventual impairments in a timely manner.
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